YCR Cancer Research Unit, Department of Biology, University of York , Heslington, York YO10 5DD, United Kingdom.
Hum Gene Ther. 2012 Feb;23(2):218-30. doi: 10.1089/hum.2011.021. Epub 2011 Sep 9.
Ad[I/PPT-E1A] is an oncolytic adenovirus that specifically kills prostate cells via restricted replication by a prostate-specific regulatory element. Off-target replication of oncolytic adenoviruses would have serious clinical consequences. As a proposed ex vivo test, we describe the assessment of the specificity of Ad[I/PPT-E1A] viral cytotoxicity and replication in human nonprostate primary cells. Four primary nonprostate cell types were selected to mimic the effects of potential in vivo exposure to Ad[I/PPT-E1A] virus: bronchial epithelial cells, urothelial cells, vascular endothelial cells, and hepatocytes. Primary cells were analyzed for Ad[I/PPT-E1A] viral cytotoxicity in MTS assays, and viral replication was determined by hexon titer immunostaining assays to quantify viral hexon protein. The results revealed that at an extreme multiplicity of infection of 500, unlikely to be achieved in vivo, Ad[I/PPT-E1A] virus showed no significant cytotoxic effects in the nonprostate primary cell types apart from the hepatocytes. Transmission electron microscopy studies revealed high levels of Ad[I/PPT-E1A] sequestered in the cytoplasm of these cells. Adenoviral green fluorescent protein reporter studies showed no evidence for nuclear localization, suggesting that the cytotoxic effects of Ad[I/PPT-E1A] in human primary hepatocytes are related to viral sequestration. Also, hepatocytes had increased amounts of coxsackie adenovirus receptor surface protein. Active viral replication was only observed in the permissive primary prostate cells and LNCaP prostate cell line, and was not evident in any of the other nonprostate cells types tested, confirming the specificity of Ad[I/PPT-E1A]. Thus, using a relevant panel of primary human cells provides a convenient and alternative preclinical assay for examining the specificity of conditionally replicating oncolytic adenoviruses in vivo.
Ad[I/PPT-E1A] 是一种溶瘤腺病毒,通过前列腺特异性调节元件的受限复制特异性杀死前列腺细胞。溶瘤腺病毒的脱靶复制将产生严重的临床后果。作为一种拟议的离体测试,我们描述了评估 Ad[I/PPT-E1A]病毒细胞毒性和在人非前列腺原代细胞中的复制特异性。选择了四种原代非前列腺细胞类型来模拟体内潜在接触 Ad[I/PPT-E1A]病毒的影响:支气管上皮细胞、尿路上皮细胞、血管内皮细胞和肝细胞。通过 MTS 测定分析原代细胞对 Ad[I/PPT-E1A]病毒的细胞毒性,通过 hexon 滴度免疫染色测定来确定病毒 hexon 蛋白的复制。结果表明,在极大概率感染 500 倍的情况下,Ad[I/PPT-E1A]病毒在非前列腺原代细胞类型中除肝细胞外,没有明显的细胞毒性作用。透射电子显微镜研究显示,大量 Ad[I/PPT-E1A]病毒被这些细胞的细胞质隔离。腺病毒绿色荧光蛋白报告基因研究没有显示核定位的证据,这表明 Ad[I/PPT-E1A]在人原代肝细胞中的细胞毒性作用与病毒隔离有关。此外,肝细胞具有更多的柯萨奇腺病毒受体表面蛋白。只有在允许的原代前列腺细胞和 LNCaP 前列腺细胞系中观察到活性病毒复制,在测试的任何其他非前列腺细胞类型中均未发现,这证实了 Ad[I/PPT-E1A]的特异性。因此,使用相关的原代人细胞面板为检查条件性复制溶瘤腺病毒在体内的特异性提供了一种方便的替代临床前测定。